Case guide

Which Drug Did You Use? Check These Three Names

These three drug names do not mean one product or one claim. Check the ingredient, form and diagnosis in your records.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202615 sources

This may apply to you if

  • Tell the lawyer the exact drug you used and when you used it.
  • Bring the gut diagnosis and test results in your medical chart.
  • Describe symptoms before and after the drug, including other health problems.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Karen Spencer Marston · United States District Court for the Eastern District of Pennsylvania · United States District Judge

Finding: The August 28, 2026 order set a September 14–18 evidence hearing in the gut case group. A hearing date is not a verdict or a personal payment date.

GI evidence-hearing scheduling order, Document 881 (opens in a new tab) · Aug 28, 2026 · Checked Oct 3, 2026

Mohit Sodhi · Faculty of Medicine, University of British Columbia · First-listed study author

Finding: The 2023 JAMA claims-record study found links between semaglutide or liraglutide use and some gut diagnoses. The observed links do not prove the cause of one person’s illness.

Sodhi original gastrointestinal cohort study (opens in a new tab) · Oct 5, 2023 · Checked Oct 3, 2026

The evidence and its limits

University of British Columbia and StatExpert Ltd · JAMA · 2023

Claims-record study of two GLP-1 drugs and gut diagnoses

Design:
Cohort
Participants:
5,411 users: 613 semaglutide, 4,144 liraglutide and 654 comparison-drug users
Finding:
The pooled GLP-1 group had higher rates of pancreatitis, bowel blockage and delayed stomach emptying than the comparison group.
Main limitation
Observational claims data, no body-mass-index data, and uncertainty about each person’s reason for use. It does not prove individual causation or risk for every GLP-1 drug.

Read the source: Claims-record study of two GLP-1 drugs and gut diagnoses (opens in a new tab) · Checked Oct 3, 2026

The short answer

Are these three names the same medicine?
No. The three names do not all mean the same drug. The full ingredient and form in your records matter. [5]
Do current labels prove my past use?
A current label can help you check a name. It cannot replace your own dated prescription and pharmacy files. Past use and the actual product need separate confirmation. [14]
Are gut and eye lawsuits one group?
No. The federal GI group and NAION group are distinct. Ask which actual diagnosis and court record match your concern. [1]
Does one study show equal risks for all three?
No. Check which drugs and patients were studied. A finding in one comparison cannot assign the same risk or personal cause to every product. [4]

What rules a case out

Not covered by this case

  • This is not a drug choice or switching plan.
  • A finding about one drug is not equal risk for every drug.
  • No case acceptance or payout is guaranteed.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

These three drug names do not mean one product or one claim. Check the ingredient, form and diagnosis in your records. Ask your clinician about care and a lawyer about any claim.

Are these three names the same medicine?

No. The three names do not all mean the same drug. The full ingredient and form in your records matter.

The checked Ozempic injection label names semaglutide. The Wegovy record also names semaglutide and shows shots and tablets. The checked Mounjaro label names tirzepatide and a shot form. Your records must confirm what you took.

Do current labels prove my past use?

A current label can help you check a name. It cannot replace your own dated prescription and pharmacy files. Past use and the actual product need separate confirmation.

DailyMed names a Novo Nordisk packager for its Wegovy record. The Mounjaro label names Eli Lilly and Company in its report-contact line. A current record does not prove who supplied every dose you took. Check the actual product and date.

Are gut and eye lawsuits one group?

No. The federal GI group and NAION group are distinct. Ask which actual diagnosis and court record match your concern.

The GI overview describes disputed allegations about named products. The NAION transfer order concerns a separate optic-nerve injury group. A product appearing in court papers does not establish that it caused every alleged condition.

Does one study show equal risks for all three?

No. Check which drugs and patients were studied. A finding in one comparison cannot assign the same risk or personal cause to every product.

Sodhi’s study abstract compares semaglutide and liraglutide use with a different treatment. It uses past billing records, with gaps in clinical detail. It cannot prove equal effects for these three brands or explain your own illness.

Which records help compare my actual use?

Keep drug names, forms, dates and care reports. Note any switch to a new drug. Ask your doctor what the report says, and do not guess facts you lack.

A covered provider can explain access to existing records. Keep prescription history separate from an online drug comparison. Do not alter the recorded eye or gut diagnosis to match the name of a lawsuit group.

What are the next care and claim checks?

Ask your own doctor about care and which drug to use. Check time limits and fees with a lawyer. Find out who gets your files before you share them.

The labels give prescribing information. They do not make this page a plan for your care. A legal inquiry does not file a suit or prove a company is at fault. Ask which law and fee terms fit your claim.

Scientific evidence for this case

Ozempic and GLP-1 gut injury claims · JAMA Ophthalmology · 2024Cohort

Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

Type 2 diabetes patients: 8.9% NAION risk on semaglutide vs 1.8% on non-semaglutide medications

Ozempic and GLP-1 gut injury claims · JAMA · 2023Cohort

Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss

Gastroparesis hazard ratio: 3.67 (95% CI 1.15-11.90)

Ozempic and GLP-1 gut injury claims · Clinical Gastroenterology and Hepatology · 2024Meta-analysis

GLP-1 Receptor Agonists and Gallbladder Disease: A Systematic Review of Randomized Controlled Trials

37% increased relative risk of gallbladder disease across 76 RCTs

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Questions about this guide

Can I file a claim if I used Trulicity instead of Ozempic?

It depends on your facts and the deadline that applies. The public Ozempic or GLP-1 source reviewed here does not decide any one person's eligibility or filing deadline. A lawyer can check your records, dates, and state law before you rule yourself out.

Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026

What is the difference between Ozempic and Wegovy?

It depends on the facts of the Ozempic or GLP-1 issue. The source reviewed here gives public context, but it does not decide causation, eligibility, payment, or deadline for one person. A lawyer can review your records and the law that applies.

Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026

Is Zepbound safer than Ozempic?

It depends. Ask your prescriber or specialist about diagnosis, testing, and medication changes. The Ozempic label lists serious gastrointestinal warnings and postmarketing reports, but it does not decide what caused one person's injury. Keep prescription, hospital, test, and diagnosis records for review.

Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026

Sources

  1. Court GI case-group overviewCourt GI case-group overview · court
  2. August 28, 2026 GI hearing scheduleAugust 28, 2026 GI hearing schedule · court
  3. NAION transfer orderNAION transfer order · court
  4. Sodhi original gastrointestinal cohort studySodhi original gastrointestinal cohort study · study
  5. FDA Ozempic prescribing information, May 2026FDA Ozempic prescribing information, May 2026 · regulator
  6. NIDDK gastroparesis definitionNIDDK gastroparesis definition · regulator
  7. NIDDK gastroparesis diagnosisNIDDK gastroparesis diagnosis · regulator
  8. NIDDK symptoms and care warningsNIDDK symptoms and care warnings · regulator
  9. ABA Model Rule 1.5 fee questionsABA Model Rule 1.5 fee questions
  10. Court filing-time guideCourt filing-time guide · court
  11. Federal covered-record access ruleFederal covered-record access rule · regulator
  12. U.S. Courts civil-case guideU.S. Courts civil-case guide · court
  13. FDA Issues Class I Recall for Omnipod 5 Insulin Pods Over Leak Riskapi.fda.gov · Jul 14, 2026 · regulator
  14. DailyMed: Wegovy Product Label Identity
  15. FDA-hosted Mounjaro Label: Product IdentityFDA-hosted Mounjaro Label: Product Identity · regulator

Checked against 15 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026